GSK says Ris—Rez Phase III ARTEMIS—008 showed efficacy in China
GSK highlighted Ris—Rez (an ADC) Phase III ARTEMIS—008 update from China, citing a 54% reduction in risk of death versus topotecan and longer median survival for ADC-treated patients.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.